Corso Giovanni, Pedrazzani Corrado, Marrelli Daniele, Pascale Valeria, Pinto Enrico, Roviello Franco
Sezione di Chirurgia Oncologica, Dipartimento di Patologia Umana e Oncologia, Policlinico Le Scotte, University of Siena, 53100 Siena, Italy.
Arch Surg. 2009 Aug;144(8):722-7. doi: 10.1001/archsurg.2009.42.
Microsatellite instability (MSI) correlates with clinicopathologic characteristics and long-term prognosis in patients having gastric carcinoma.
Analysis of prospectively collected data and biologic material.
Tertiary University Hospital, Policlinico "Le Scotte," Siena, Italy.
Two hundred fifty patients with gastric carcinoma.
Five mononucleotide repeats (BAT-26, BAT-25, NR-24, NR-21, and NR-27) were analyzed in these patients.
An MSI phenotype was identified in 63 patients (25.2%) and correlated with specific clinicopathologic characteristics. Favorable prognosis was confirmed for patients with an MSI phenotype in univariate (P < .001) and multivariate (P = .05) analyses. Significant differences in clinicopathologic characteristics and long-term prognoses were observed among patients with microsatellite-stable tumors, tumors having instability at 2 to 4 markers, and tumors having instability at all 5 markers (MSI/5). The MSI/5 phenotype was associated with older age (P < .001), female sex (P = .001), antral tumor location (P = .04), intestinal histotype (P = .003), and less infiltration of the serosa (P = .006); lymph node involvement was rare (P < .001) and was limited to few (median, 3) metastatic lymph nodes (P = .001). Long-term survival of patients with the MSI/5 phenotype is favorable and was confirmed in multivariate analysis (relative risk vs patients with stable tumors, 0.32; 95% confidence interval, 0.16-0.63; P = .002).
Compared with stable tumors, MSI tumors have distinct clinicopathologic features and are associated with a better prognosis. Patients with the MSI/5 phenotype have a very good prognosis.
微卫星不稳定性(MSI)与胃癌患者的临床病理特征及长期预后相关。
对前瞻性收集的数据和生物材料进行分析。
意大利锡耶纳大学综合医院“Le Scotte”三级大学医院。
250例胃癌患者。
分析这些患者的五个单核苷酸重复序列(BAT-26、BAT-25、NR-24、NR-21和NR-27)。
63例患者(25.2%)被鉴定为MSI表型,且与特定临床病理特征相关。单因素分析(P <.001)和多因素分析(P =.05)均证实MSI表型患者预后良好。微卫星稳定肿瘤患者、2至4个标记不稳定的肿瘤患者和所有5个标记均不稳定的肿瘤(MSI/5)患者在临床病理特征和长期预后方面存在显著差异。MSI/5表型与年龄较大(P <.001)、女性(P =.001)、胃窦部肿瘤位置(P =.04)、肠型组织学(P =.003)及浆膜浸润较少(P =.006)相关;淋巴结受累罕见(P <.001),且局限于少数(中位数为3个)转移淋巴结(P =.001)。MSI/5表型患者的长期生存率良好,多因素分析证实了这一点(与稳定肿瘤患者相比,相对风险为0.32;95%置信区间为0.16 - 0.63;P =.002)。
与稳定肿瘤相比,MSI肿瘤具有独特的临床病理特征,且预后较好。MSI/5表型患者预后非常好。